Last Updated: 16 Sep 2024
Executive Summary
AbbVie Inc. (ABBV) is a leading biopharmaceutical company with a strong track record of financial performance. The company has a diverse portfolio of products, including blockbuster drugs such as Humira and Imbruvica. AbbVie is well-positioned for continued growth, driven by its strong pipeline of new drugs and its commitment to innovation. The stock is currently trading at $194.21, below its 52-week high of $199.95. We believe that AbbVie is a good investment for long-term investors.
Company Overview
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. AbbVie is headquartered in North Chicago, Illinois. The company has a global presence, with operations in over 175 countries. AbbVie's portfolio of products includes pharmaceuticals, biologics, and medical devices. The company's key therapeutic areas include immunology, oncology, virology, and neuroscience.
Fundamental Analysis
AbbVie has a strong financial profile. The company has a market capitalization of $343 billion and an EBITDA of $26.1 billion. AbbVie's profit margin is 9.71%, and its operating margin is 34.6%. The company's return on assets is 7.94%, and its return on equity is 54.3%. AbbVie has a strong balance sheet, with $17.6 billion in cash and equivalents and $23.5 billion in long-term debt.
Technical Analysis
AbbVie's stock price has been trading in a range between $132.11 and $199.95 over the past 52 weeks. The stock is currently trading at $194.21, near the middle of its range. The 50-day moving average is $186.25, and the 200-day moving average is $171.05. The relative strength index (RSI) is 52.4, indicating that the stock is not overbought or oversold.
Short Term Outlook
We believe that AbbVie's stock is fairly valued at current levels. The stock is trading at a trailing PE of 64.95 and a forward PE of 16.13. The stock's dividend yield is 3.19%. We expect AbbVie to continue to grow its earnings and dividends in the future.
Long Term Outlook
We believe that AbbVie is a good investment for long-term investors. The company has a strong pipeline of new drugs, and it is well-positioned to benefit from the growing demand for biopharmaceuticals. We expect AbbVie to continue to grow its earnings and dividends in the future.
Analyst Recommendations
The consensus analyst rating on AbbVie is "buy." The average analyst target price is $197.33. Four analysts have a "strong buy" rating on the stock, 17 have a "buy" rating, 9 have a "hold" rating, and 0 have a "sell" or "strong sell" rating.
